Global rules could cut costs and speed access to GLP-1 drugs

by University of California, San Francisco

edited by Sadie Harley, reviewed by Robert Egan

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Associate Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

FDA-approved carbon copies of brand-name drugs with expired patents—over the last 30 years, these generic drugs have saved trillions of dollars for hundreds of millions of people.

But newer biologic medicines, including blockbuster treatments for diabetes, cancer, and autoimmune disease, are harder to manufacture into generic form. Unlike traditional "small molecule" drugs made from chemicals, biologics are large, protein-sized molecules made in living cells. Their equivalents, called biosimilars, are close but not identical copies.

Now, a study by UC San Francisco researchers shows that the regulations for biosimilars vary around the world, slowing their development and adoption.

"Just 5% of prescriptions are for biologics like Ozempic, but they make up more than half of all drug spending," said Jonathan Watanabe, PharmD, MS, Ph.D., chair of the UCSF Department of Clinical Pharmacy and first author of the paper, which appears in JAMA Health Forum.

"Yet many countries aren't equipped to quickly vet and approve of new biosimilars, limiting access for patients."

Generics transformed the prescription drug market in large part because regulators like the U.S. Food and Drug Administration (FDA) lean on the records of brand-name drugs to approve them. But biosimilars, which can vary from the original biologic, aren't afforded the same streamlined process.

Watanabe and his colleagues dug into biosimilar regulations across 19 countries, including the U.S., Canada, United Kingdom, Nigeria, Brazil, Egypt, and Indonesia. Most countries used similar language to describe biosimilars at first, but their rules for approving them quickly diverged.

Some countries were comfortable approving biosimilars if they were "similar enough" to the biologic in laboratory tests, while others demanded more testing in patients. Some authorized pharmacists to substitute a biosimilar for a biologic at the pharmacy counter, while others required the prescribing doctor to approve or write a new prescription. And some were open to using data and studies from trusted foreign regulators, while others required companies to repeat studies locally.

The researchers say that aligning biosimilar approval across countries could make it easier for biosimilars to reach the market—and hopefully lower costs for all patients, just like generics.

"Generics represent one of the biggest success stories of the pharmaceutical industry in terms of making life-extending treatments more affordable, and we hope our study helps biosimilars do the same," Watanabe said.

Publication details

Jonathan H. Watanabe et al, Regulatory Definitions and Classification of Biosimilar Medications Across the 6 Regions of the World Health Organization, JAMA Health Forum (2026). DOI: 10.1001/jamahealthforum.2026.1642

Journal information: JAMA Health Forum

Key medical concepts

Drugs, GenericSemaglutideDiabetes

Clinical categories

Clinical pharmacology Provided by University of California, San Francisco Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Global rules could cut costs and speed access to GLP-1 drugs (2026, June 1) retrieved 1 June 2026 from https://medicalxpress.com/news/2026-06-global-access-glp-drugs.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.